No Detail Found!

Efficacy of Daclatasvir with Sofosbuvir for Treating Chronic Hepatitis C Genotype 3

Author(s)
FAHAD AMAN KHAN Allama Iqbal Medical College/Jinnah Hospital Lahore.Pakistan
MUKHTAR AHMAD Allama Iqbal Medical College/Jinnah Hospital Lahore.Pakistan
IMRAN KHAN Allama Iqbal Medical College/Jinnah Hospital Lahore.Pakistan
ANIQA ANSER TUFAIL KHAN Azra Naheed Medical College,Lahore,Pakistan
MUHAMMAD KASHIF University College of Medicine and Dentistry, University of Lahore,Lahore,Pakistan
TASHIA MALIK Jinnah Hospital Lahore,Pakistan
Abstract
To determine efficacy of Daclatasvir with sofosbuvir in treating patients of chronic hepatitis C genotype 3. Study Design: Interventional case-series study Place and Duration of Study: Hepatitis Clinic, Medical Unit-II, Jinnah Hospital, Lahore from January 2019 to June 2019. Methodology: One hundred and thirty five patients of chronic hepatitis C Genotype 3 were enrolled. All patients were givendaclatasvir60mg and sofosbuvir 400mg once-daily for 12 weeks. HCV-RNA-PCR was done at end of 12 weeks of treatment (ETR) and 12 weeks after end of treatment (SVR). Results: The mean age of the patients was 49.8?±2.3 years. There were 57.7% males while 42.2% females with 22.2% frequency of cirrhosis in them.The mean value of AST and ALT was calculated as 57.07?±?48.69 and 51.02?±?44.17 IU/ml respectively in hepatitis C patients having genotype 3.The treatment follow up showed that on reassessing the hepatitis C status through quantitative analysis of genotype 3 through PCR it was seen that 91.1% patients reached SVR with no viral detection in them. Conclusion: Daclatasvir in combination to sofosbuvir is an efficient way of treating hepatitis C patients suffering from genotype 3.
Publication Details
Page(s) 240-241
DOI DOI not available
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 05, Year: 2022

Request the full text from PASTIC

Keywords
HCV, Sofosbuvir, Viral load, Genotype 3
References
Liver Int2011 . .. , 31(Suppl 2) : 1-3.
Shah HA,Jafri W,Malik I .1997 .Hepatitis C virus genotypes and chronic liver disease in Pakistan. J GastroenterolHepatol, 12 : 758-61.
Idrees M,Riazuddin S.,Bousquet V,Delarocque-Astagneau E .2008 .HCV Surveillance Steering Committee Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol2010;, 82 : 1647-54.
.2014 .. JAMA Intern Med, 174 : 204-12.
Wang C,Valera L,Jia L,Kirk MJ,Gao M,Fridell RA. . .In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. , 57 : 611-3.
.2013 .. N Engl J Med, 368 : 1878-87.
Nelson DR,Cooper JN,Lalezari JP . .All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. J Hepatol2015, 61(4) : 1127-35.
Sulkowski MS,Gardiner DF,Rodriguez-Torres M .2014 .Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med, 370(3) : 211-21.
Umer M,Iqbal M .2016 .Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol, 22(4) : 1684.
Sulkowski MS,Jacobson IM,Nelson DR .2014 .Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med, 370(16) : 1560.
.2018 .HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: results from ERCHIVES. Liver Int, 38(8) : 1411-7.
.2018 .Daclatasvir and asunaprevir inhemodialysis patients with hepatitis C virus infection: a nationwideretrospective study in Japan. J Gastroenterol, 53(1) : 119-28.
Atsukawa M,Tsubota A,Toyoda H,Takaguchi K,Nakamuta M,Watanabe T . .The efficacy andsafety of glecaprevir plus pibrentasvir in 141 patients with severe renalimpairment: a prospective, multicenter study. , : .
.2019 .. Aliment PharmacolTher, 49(9) : 1230-41.
Atsukawa M,Tsubota A,Koushima Y,Ikegami T,Watanabe K,Shimada N .2017 .Efficacy and safety of ombitasvir/ paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res, 47(13) : 1429-37.
Li T,Qu Y,Guo Y,Wang Y,Wang L Y .2017 .Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4- 5 chronic kidney disease: a meta-analysis. Liver Int, 37(7) : 974-81.
Agarwal SK,Bagchi S,Yadav RK .2017 .Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep, 2(5) : 831-5.
Safety .2014 .Anti-viral Efficacy and Pharmacokinetics (pk) of Sofosbuvir (sof) in patients with severe renal impairment. Hepatology, 60 : 667A.
Desnoyer A,Pospai D,Lê MP,Gervais A,Heurgué-Berlot A,Laradi A .2016 .Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol, 65(1) : 40-7.
Ram BK,Frank C,Adam P,Cynthia L,Maria H,Lennox J .2015 .Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol, 63(3) : 763.
0

Citations

0

Downloads

128

Views